New Device and Diagnostics Legislation Could Shake Up the Drug Industry | Diaceutics

New Device and Diagnostics Legislation Could Shake Up the Drug Industry

September 23rd, 2013

Patrick Considine

Patrick Considine of Diaceutics comments on the 2013 proposals by the European Parliament’s Health Committee to introduce new legislation for devices and in vitro diagnostics. 

This month [September 2013], the European Parliament’s Health Committee will reach its view on the two major proposals launched last year by EU officials — one on devices, and one on in vitro diagnostics. In October, the parliament as a whole is due to agree its definitive opinion on the proposals. And before the end of the year, the governments of the EU’s 28 member states are expected to finalize their position on the proposals, too. So by early 2014, new rules should be signed off that will change the face of EU controls on these products (http://www.pharmexec.com/europe-new-device-and-diagnostics-legislation-could-shake-drug-industry).

If the proposals are passed, a number of changes impacting regulation of IVDs in the EU will be introduced:

  1. The IVD Directive would be replaced by IVD Regulations. EU member states have interpreted and implemented the current directives in different ways, which led to different levels of patient and public health protection in the European Union and created obstacles within the single market. The draft EU Regulations, which are laws unto themselves, do not need to be transposed into law within each member state, as is the case for directives.
  2. The proposed Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) classification rules which will impact the review requirement for all IVDs. Under the current IVD directive (98/79/EC), approximately 80 per cent of IVD products are grouped in the self-certification class. In the proposed Regulation only 20 per cent of IVD products will remain in the self-certification category, while a form of third-party pre-market intervention will be required for the remaining 80 per cent of products. All ‘human genetic testing’ falls into Class C. This will set a higher bar for device manufacturers than the current self-certification system. Manufacturers of Class C devices will have their quality management systems inspected by national Notified Bodies. This will make approval of IVD products more expensive and slower.
  3. The exemption from the regulations for devices manufactured and used within the same health institution (LDT) is retained, but is now restricted to health institutions compliant with ISO 15189 or other equivalent recognized standard. Labs which are not accredited would only be allowed to use CE-marked tests.

Blogs

View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications